Seladelpar for primary biliary cirrhosis – second or subsequent line

featured image
Therapeutic Areas: Hepatology
Year: 2017

Primary biliary cirrhosis (PBC), is a long-term liver disease in which the pipes (ducts) that transports bile in the liver become damaged. PBC causes the build-up of bile in the liver and eventually may lead to scarring. Nine out of ten people with PBC are women. The exact cause of PBC is not known, although family history, when combined with lifestyle may increase the risk of getting PBC. The most common symptoms of PBC are itchy skin and fatigue, however, up to half of people with PBC do not have any symptoms until extensive liver damage occurs.
Seladelpar is a new drug currently being developed and tested to treat PBC. It acts by promoting the natural transportation and storage of bile within the liver. It is currently taken as a capsule in doses of 2 mg, 5mg, 10mg, or 20mg once a day. If licensed in the UK, seladelpar could provide an additional treatment option for people with PBC.